Genotropin Miniquick Side Effects
Generic Name: somatropin
Please note - some side effects for Genotropin Miniquick may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects by Body System - for Healthcare Professionals
Applies to: injectable kit; injectable powder for injection; subcutaneous kit; subcutaneous powder for injection; subcutaneous solution
Somatropin is generally well tolerated with minimal adverse effects.
Oncologic side effects have included rare reports of leukemia, however, the association with human growth hormone is uncertain.
Immunologic adverse reactions have included the rare development of persistent antibodies in patients treated with recombinant human growth hormone. The development of antibodies may be greater with the use of somatrem than with somatropin, although the overall incidence is very low.
An IgG antibody has been identified. No antibodies to the IgE class have been detected. Growth hormone antibody binding capacities less than 2 mg/L have not led to growth attenuation. Testing for antibodies should be carried out in any patient failing to respond to treatment.
Primate studies have failed to reveal evidence of histopathological changes due to immune complex formation.
Nervous system effects have included headaches, weakness, paresthesia and hypethesia.
Musculoskeletal side effects have included localized muscle pain, carpal tunnel syndrome, aggravation of preexisting scoliosis, jaw prominence and slipped capital femoral epiphysis. Patients with Short Stature Homeobox Containing Gene (SHOX) Deficiency have reported scoliosis and arthralgia.
Endocrine side effects have included mild hyperglycemia, gynecomastia, and, rarely pancreatitis. New-onset type 2 diabetes mellitus in children and adults has been reported in postmarketing experience. Elevations in IGF-1 (insulin like growth factor 1) and insulin levels have occurred consistently in adults. Alterations in thyroid hormone metabolism may occur.
Serum levels of inorganic phosphorus, alkaline phosphatase and parathyroid hormone (PTH) may increase during treatment with somatropin. The mechanism is unknown. These potential changes should be considered when evaluating patient laboratory measurements.
During postmarketing surveillance, cases of new onset glucose intolerance, diabetes mellitus and exacerbations of preexisting diabetes mellitus have been reported in patients receiving the Serostim brand of somatropin. Some patients developed ketoacidosis and diabetic coma. In some patients, these conditions improved when Serostim was discontinued but not in all patients.
Edema occurs more often in adults, appears to be dose-related, and is due to the antinatriuretic effect of growth hormone.
Cardiovascular side effects have included mild, transient, peripheral edema in up to 2.5% of patients during early treatment with somatropin. Intracranial hypertension is a rare effect that may present with papilledema, visual changes, headache, nausea and vomiting. Postmarketing reports have included hypertension.
Athletes using human growth hormone for doping purposes may experience cardiac, renal, and splenic hypertrophy, cardiac myopathy, fluid retention, glucose intolerance, abnormal bone growth, and an increased risk of cancers.
Chronic use of human growth hormone by athletes can lead to toxicity seen in acromegaly.
There is no risk of acquiring Creutzfeldt-Jakob disease from recombinant human growth hormone, as with the previously marketed pituitary derived human growth hormone.
Dermatologic side effects have included rash, pruritus, increased sweating and increased growth of preexisting nevi (hereditary malformation of the skin). Patients with Short Stature Homeobox Containing Gene (SHOX) Deficiency have reported excessive number of cutaneous nevi.
Metabolic side effects have included mild transient hyperglycemia and lipolysis in adults which resulted in a statistically significant decrease in total body fat (14% to 20%) and a significant reductions in total cholesterol and/or LDL levels. No changes in HDL have been observed. Elderly patients have exhibited triglyceride elevations. The long-term effect of recombinant human growth hormone on lipid metabolism is unknown.
Local side effects have included localized injection site reactions and pain.
Other side effects have included an increased incidence of otitis media and other ear disorders in Turner syndrome patients. Other side effects reported in Turner syndrome patients have included influenza-like illness, upper respiratory tract infection, eczema, excessive growth of hands and feet, and exacerbation of preexisting scoliosis.
Gastrointestinal side effects have included diarrhea, nausea and vomiting.
Hypersensitivity side effects have included allergic reactions.
Respiratory side effects have included rhinitis, bronchitis and upper respiratory tract infections. Postmarketing reports have included dyspnea and sleep apnea.Top
- Genotropin Miniquick Advanced Consumer (Micromedex) - Includes Dosage Information
- Somatropin Professional Patient Advice (Wolters Kluwer)
- Genotropin Prescribing Information (FDA)
- Genotropin MedFacts Consumer Leaflet (Wolters Kluwer)
- Humatrope cartridge MedFacts Consumer Leaflet (Wolters Kluwer)
- Humatrope Prescribing Information (FDA)
- Norditropin MedFacts Consumer Leaflet (Wolters Kluwer)
- Norditropin Prescribing Information (FDA)
- Nutropin Prescribing Information (FDA)
- Nutropin Subcutaneous, Injection Advanced Consumer (Micromedex) - Includes Dosage Information
- Nutropin MedFacts Consumer Leaflet (Wolters Kluwer)
- Nutropin AQ Prescribing Information (FDA)
- Nutropin AQ MedFacts Consumer Leaflet (Wolters Kluwer)
- Nutropin Depot Prescribing Information (FDA)
- Omnitrope Prescribing Information (FDA)
- Omnitrope MedFacts Consumer Leaflet (Wolters Kluwer)
- Omnitrope Consumer Overview
- Saizen Prescribing Information (FDA)
- Saizen MedFacts Consumer Leaflet (Wolters Kluwer)
- Serostim Prescribing Information (FDA)
- Serostim MedFacts Consumer Leaflet (Wolters Kluwer)
- Tev-Tropin MedFacts Consumer Leaflet (Wolters Kluwer)
- Tev-Tropin Prescribing Information (FDA)
- Zorbtive Prescribing Information (FDA)
- Zorbtive MedFacts Consumer Leaflet (Wolters Kluwer)
- Zorbtive Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.